Crossject secures funding from French Government for needle-free platform
The cash injection will accelerate the development of Crossject’s prefilled needle free platform to treat anaphylactic shock.
The cash injection will accelerate the development of Crossject’s prefilled needle free platform to treat anaphylactic shock.
What's Your Reaction?
